Abstract | OBJECTIVE: METHODS: RESULTS: HbA(1c), FPG and body weight were all significantly reduced after treatment with insulin detemir for 6 months, without increasing severe hypoglycaemia. Insulin dose increased significantly over the same time. There were significant improvements in overall nocturnal quality of life, as well as well-being. CONCLUSIONS: Treatment with insulin detemir for 6 months resulted in substantial benefits, including reduced HbA(1c), FPG and body weight, and improvements in nocturnal quality of life, without increasing hypoglycaemia.
|
Authors | M Oishi, N Abe, H Yokoyama, N Kuribayashi, O Tomonaga, K Matoba, M Kobayashi, Japan Diabetes Clinical Data Management Study Group |
Journal | The Journal of international medical research
(J Int Med Res)
Vol. 40
Issue 2
Pg. 787-97
( 2012)
ISSN: 1473-2300 [Electronic] England |
PMID | 22613444
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Blood Glucose
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Insulin, Long-Acting
- Insulin Detemir
- Insulin, Isophane
|
Topics |
- Blood Glucose
(analysis)
- Blood Glucose Self-Monitoring
- Diabetes Mellitus, Type 2
(blood, drug therapy)
- Drug Administration Schedule
- Female
- Glycated Hemoglobin
(analysis)
- Humans
- Hypoglycemia
(blood)
- Hypoglycemic Agents
(therapeutic use)
- Insulin Detemir
- Insulin, Isophane
(therapeutic use)
- Insulin, Long-Acting
(therapeutic use)
- Japan
- Male
- Middle Aged
- Quality of Life
- Surveys and Questionnaires
|